USMI to Announce Successful Results of Phase I Clinical Trial Using Cold Atmospheric Plasma for the Treatment of Solid Tumors at the Baird 2021 Global Healthcare Conference

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI), a U.S. FDA-registered life-science and biomedical device company and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that Jerome Canady MD, CEO will be presenting at the Baird Global Healthcare Conference on Tuesday, September 14^th from 10:15 to 10:45 AM ET.

Dr. Canady will present results from their FDA-approved Phase I Clinical Trial evaluating Cold Atmospheric Plasma for the treatment of Stage IV, Recurrent, Metastatic Solid tumors (FDA IDE #190165) and their recent discovery identifying the mechanism in which Canady Helios™ Cold Plasma induces apoptosis in breast cancer. JCRI-ABTS Discovers the Mechanism using Canady Helios™ Cold Plasma to Induce Cell Death in Breast Cancer.

The trial was completed April 15, 2021 at Rush University Medical Center (Chicago, IL) and Sheba Medical Center-Tel HaShomer (Ramat Gan, Israel). The Principal Investigators were Professor Steven Gitelis, M.D., and Professor Aviram Nissan, M.D. respectively.

About USMI

USMI is a private U.S. biomedical device company and wholly owned subsidiary of US Patent Innovations, LLC. USMI’s focus is developing advanced innovative affordable plasma and robotic electrosurgical devices and striving to develop innovative devices in the field of plasma technology for the eradication of cancer.

About JCRI-ABTS

JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory focusing on Plasma Oncotherapeutics (a new cancer treatment modality) using Canady Helios™ Cold Plasma to investigate the potential of Cold Atmospheric Plasma to selectively treat cancer.